Corbus Pharmaceuticals Announces Positive Phase 1b CRB-913 Obesity Trial Results

What Happened

• On September 14, 2026 Corbus Pharmaceuticals (CRBP) filed an 8‑K and issued a press release reporting positive topline data from CANYON‑1, a 16‑week, double‑blind, placebo‑controlled Phase 1b trial (NCT07310901) of oral CRB‑913 for obesity. The data were selected for a late‑breaking presentation at ObesityWeek® 2026.
• The study enrolled 254 obese, non‑diabetic adults across 15 U.S. sites, randomized 1:1:1:1 to placebo or CRB‑913 at 20 mg, 40 mg, or 60 mg once daily (12 weeks dosing + 4 weeks follow‑up). Least‑squares mean percent weight change at week 12: placebo 0.0%, CRB‑913 20 mg 2.8%, 40 mg 3.3%, 60 mg 5.0% (all p < 0.0001 vs placebo). At 60 mg, 44.4% of completers lost ≥5% body weight; max recorded loss was 13.4%.
• The company reported a favorable safety and tolerability profile, with CRB‑913 showing fewer gastrointestinal adverse events in cross‑trial comparisons to marketed oral GLP‑1s and low rates of psychiatric events (one transient moderate depressive symptom among 188 participants dosed with CRB‑913; no suicidality).

Key Details

• Trial: CANYON‑1 Phase 1b, 254 participants, 16‑week study (12‑week dosing + 4‑week follow‑up), NCT07310901.
• Efficacy: LS mean weight change at week 12 — placebo 0.0%, 20 mg 2.8%, 40 mg 3.3%, 60 mg 5.0% (p < 0.0001 vs placebo).
• Responder rates: 44.4% of 60 mg completers achieved ≥5% weight loss; 6.7% lost >7.5%.
• Safety: Treatment discontinuations for CRB‑913 = 3.1%–13.1% (company notes this is in line or lower than approved oral GLP‑1s); GI and psychiatric AEs described as generally mild/moderate and less frequent than some comparators per cross‑trial comparisons.

Why It Matters

• These topline Phase 1b results signal that CRB‑913 may produce rapid, clinically meaningful weight loss with a tolerability profile that could differentiate it from current oral GLP‑1 therapies. For investors, this supports the program’s clinical potential and the company’s messaging ahead of the ObesityWeek presentation.
• Important caveats from the filing: comparisons to other drugs are cross‑trial and not head‑to‑head; this is early (Phase 1b) data — larger, controlled trials will be needed to confirm efficacy and safety before regulatory decisions or commercialization.